PL2022497T3 - Doustna kompozycja zawierająca kwas 3-{5-[4-(cyklopentyloksy)-2-hydroksybenzoilo]-2-[(3-hydroksy-1,2-benzizoksazol-6-ilo)metoksy]fenylo}propionowy lub jego sól - Google Patents

Doustna kompozycja zawierająca kwas 3-{5-[4-(cyklopentyloksy)-2-hydroksybenzoilo]-2-[(3-hydroksy-1,2-benzizoksazol-6-ilo)metoksy]fenylo}propionowy lub jego sól

Info

Publication number
PL2022497T3
PL2022497T3 PL07744105T PL07744105T PL2022497T3 PL 2022497 T3 PL2022497 T3 PL 2022497T3 PL 07744105 T PL07744105 T PL 07744105T PL 07744105 T PL07744105 T PL 07744105T PL 2022497 T3 PL2022497 T3 PL 2022497T3
Authority
PL
Poland
Prior art keywords
benzisoxazol
hydroxybenzoyl
cyclopentyloxy
methoxy
hydroxy
Prior art date
Application number
PL07744105T
Other languages
English (en)
Inventor
Sahoe Kakuda
Tatsuhito Yahata
Masashi Kaneko
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of PL2022497T3 publication Critical patent/PL2022497T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL07744105T 2006-05-26 2007-05-25 Doustna kompozycja zawierająca kwas 3-{5-[4-(cyklopentyloksy)-2-hydroksybenzoilo]-2-[(3-hydroksy-1,2-benzizoksazol-6-ilo)metoksy]fenylo}propionowy lub jego sól PL2022497T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006146257 2006-05-26
JP2006146315 2006-05-26
PCT/JP2007/060671 WO2007138997A1 (ja) 2006-05-26 2007-05-25 ３－｛５－［４－（シクロペンチルオキシ）－２－ヒドロキシベンゾイル］－２－［（３－ヒドロキシ－１，２－ベンズイソオキサゾール－６－イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する経口用組成物
EP07744105.3A EP2022497B1 (en) 2006-05-26 2007-05-25 Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof

Publications (1)

Publication Number Publication Date
PL2022497T3 true PL2022497T3 (pl) 2014-09-30

Family

ID=38778517

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07744105T PL2022497T3 (pl) 2006-05-26 2007-05-25 Doustna kompozycja zawierająca kwas 3-{5-[4-(cyklopentyloksy)-2-hydroksybenzoilo]-2-[(3-hydroksy-1,2-benzizoksazol-6-ilo)metoksy]fenylo}propionowy lub jego sól

Country Status (21)

Country Link
US (1) US8093289B2 (pl)
EP (1) EP2022497B1 (pl)
JP (1) JP5161077B2 (pl)
KR (1) KR101394121B1 (pl)
CN (1) CN101454003B (pl)
AU (1) AU2007268772B2 (pl)
BR (1) BRPI0709710A2 (pl)
CA (1) CA2653023C (pl)
CY (1) CY1115312T1 (pl)
DK (1) DK2022497T3 (pl)
ES (1) ES2463455T3 (pl)
IL (1) IL195417A (pl)
MX (1) MX2008015015A (pl)
NO (1) NO20084634L (pl)
NZ (1) NZ573035A (pl)
PL (1) PL2022497T3 (pl)
PT (1) PT2022497E (pl)
RU (1) RU2436576C2 (pl)
SI (1) SI2022497T1 (pl)
WO (1) WO2007138997A1 (pl)
ZA (1) ZA200810018B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959502A (zh) * 2008-03-04 2011-01-26 弗·哈夫曼-拉罗切有限公司 制备浓缩胶束水溶液的方法
SG188816A1 (en) * 2008-03-27 2013-04-30 Toyama Chemical Co Ltd Use of benzophenone derivative or salt thereof and tnf alpha inhibitor in combination and pharmaceutical composition containing the derivative or salt thereof and the inhibitor
CA2721920A1 (en) 2008-04-22 2009-10-29 Toyama Chemical Co., Ltd. Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
WO2014056942A1 (en) * 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
CN110575762B (zh) * 2018-06-07 2024-03-26 温州大学新材料与产业技术研究院 一种有机烷基钆水性分散体系的制备方法
WO2021257887A1 (en) * 2020-06-19 2021-12-23 The Board Of Trustees Of The Leland Stanford Junior University Use of inhibitors of the activator protein 1 (ap-1) for preventing adhesions
JP7495340B2 (ja) * 2020-12-16 2024-06-04 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法
CN118255728B (zh) * 2024-01-25 2024-07-30 中国医学科学院阜外医院 化合物的盐型晶型用于治疗射血分数保留的心衰的用途
CN118252824B (zh) * 2024-01-25 2024-09-17 中国医学科学院阜外医院 化合物用于治疗射血分数保留的心衰的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670080A (en) * 1969-03-06 1972-06-13 Shionogi & Co Process for stabilization of a composition of 2{60 ,3{60 -epithio-androstanes and composition obtained thereby
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
JPS56110612A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
JPS5942313A (ja) * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
JPS60190723A (ja) * 1984-03-09 1985-09-28 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
MXPA04004654A (es) * 2001-11-16 2005-05-17 Toyama Chemical Co Ltd Novedosos derivados de benzofenona o sus sales.

Also Published As

Publication number Publication date
US20090163562A1 (en) 2009-06-25
CA2653023C (en) 2015-07-07
EP2022497A1 (en) 2009-02-11
DK2022497T3 (da) 2014-05-19
IL195417A0 (en) 2009-08-03
IL195417A (en) 2014-03-31
SI2022497T1 (sl) 2014-08-29
CN101454003A (zh) 2009-06-10
AU2007268772B2 (en) 2012-03-15
CA2653023A1 (en) 2007-12-06
WO2007138997A1 (ja) 2007-12-06
RU2436576C2 (ru) 2011-12-20
BRPI0709710A2 (pt) 2011-07-26
JPWO2007138997A1 (ja) 2009-10-08
KR20090021167A (ko) 2009-02-27
NZ573035A (en) 2010-08-27
EP2022497B1 (en) 2014-04-30
EP2022497A4 (en) 2013-02-13
KR101394121B1 (ko) 2014-05-14
NO20084634L (no) 2008-12-19
AU2007268772A1 (en) 2007-12-06
ZA200810018B (en) 2010-02-24
MX2008015015A (es) 2008-12-05
US8093289B2 (en) 2012-01-10
CN101454003B (zh) 2011-06-01
RU2008151757A (ru) 2010-07-10
ES2463455T3 (es) 2014-05-28
CY1115312T1 (el) 2017-01-04
JP5161077B2 (ja) 2013-03-13
PT2022497E (pt) 2014-07-17

Similar Documents

Publication Publication Date Title
PL2022497T3 (pl) Doustna kompozycja zawierająca kwas 3-{5-[4-(cyklopentyloksy)-2-hydroksybenzoilo]-2-[(3-hydroksy-1,2-benzizoksazol-6-ilo)metoksy]fenylo}propionowy lub jego sól
ZA200906542B (en) Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenyl-imidazolone compounds as ²-secretase inhibitors
PL2099297T3 (pl) Środki poprawiające zgodność dla preparatów herbicydów zawierających sole kwasu 2,4-(dichlorofenoksy)octowego
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
PT2003132E (pt) Derivados de oxadiazole como agonistas dos s1p1
BRPI0912855A2 (pt) derivados de indazóis substituídos por fenila ou piridinila
ZA200802636B (en) Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE)
DE602006004694D1 (de) Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
IL200401A0 (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
IL178056A0 (en) Oxadiazolone derivatives as ppar delta agonists
RU2008151778A (ru) Новые кристаллы 3-[5-[4-(циклопентилокси)-2-гидроксибензоил]-2-[(3-гидрокси-1,2-бензизоксазол-6-ил)метокси]фенил]пропиновой кислоты
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
SI1988085T1 (sl) Postopek za izdelavo 3-(5-(4-(ciklopentiloksi)-2-hidroksibenzoil)-2-((3 -hidroksi-1,2-benzizoksazol-6-il)metoksi)fenil)propionat estra in intermediata za ta postopek
ZA200807190B (en) Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
WO2009069643A1 (ja) ３－｛５－［４－（シクロペンチルオキシ）－２－ヒドロキシベンゾイル］－２－［（３－ヒドロキシ－１，２－ベンズイソオキサゾール－６－イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する固体分散体またはその組成物
FR2927930B1 (fr) Joue universelle pour volet roulant.
SE0801603L (sv) Låsmekanism för ventilationsdon
ZA201000624B (en) Thermodynamically stable crystal modification of 2-({2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy) methyl]phenyl}carbonyl)cyclohexane-1,3-dione
HK1138843A (en) AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS
FR2907812B1 (fr) Obturateur pour tariere de forage
FI7255U1 (fi) Riistankäsittelytila
ITBO20060086A1 (it) Cricchetto universale per infissi.
UA15013S (uk) Жувальна цукерка «слід ведмедика»
UA15012S (uk) Жувальна цукерка «ведмедик»
FR2903571B1 (fr) Cages en rotation pour aquaculture.